The Texas Health and Human Services Commission (HHSC) will implement a clinical prior authorization criteria update for Dupixent (dupilumab) on January 4, 2022. The U.S. Food and Drug Administration approved Dupixent on October 20, 2021, as an add-on maintenance treatment for individuals 6 years or older with moderate to severe eosinophilic phenotype asthma or with oral corticosteroid-dependent asthma. The expanded prior authorization criteria will allow providers to prescribe Dupixient following the expanded age indication.
HHSC does not require managed care organizations (MCOs) to implement Dupixent clinical prior authorization criteria. However, MCOs using the criteria must incorporate the above revisions by January 4, 2022.
Email email@example.com with comments or questions.